Categories: News

Parexel Named Best Contract Research Organization by Scrip

Company recognized for innovative and effective use of real-world data and flexible trial designs

BOSTON and DURHAM, N.C., Dec. 03, 2020 (GLOBE NEWSWIRE) — Parexel, a leading provider of solutions to accelerate the development and delivery of innovative therapies to improve world health, from clinical through commercialization, today announced it was named the “Best Contract Research Organization” in the Full-Service Provider category at the Digital 16th Annual Scrip Awards. The award was presented at the virtual awards ceremony Dec. 2.

“This award belongs to our exceptionally talented staff — the people working tirelessly to deliver critical insights for our customers and improve patient outcomes,” said Jamie Macdonald, Chief Executive Officer. “We are honored to be recognized as the industry’s Best CRO by Scrip and even more pleased to see our industry — in the face of a global pandemic — take this opportunity to accelerate the adoption of a real-world, data-driven approach to clinical trial design to bring new therapies to patients sooner.”

The annual Scrip awards, organized by Informa Pharma Intelligence, the premier source of information for the global pharmaceutical and biomedical industry, are designed to celebrate the contributions of the pharmaceutical, biotech and other allied industries to improving human health worldwide. Parexel was selected by a distinguished panel of life science industry executives based on the company’s capabilities and strengths specifically related to delivering results to exceed sponsor expectations; providing innovative patient recruitment strategies; improving quality of data, timelines and transparency; and streamlining data collection and reporting.

About Parexel
Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life science and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From clinical trials to regulatory and consulting services to commercial and market access, our therapeutic, technical and functional ability is underpinned by a deep conviction in what we do. For more information, visit our website and follow us on LinkedInTwitter and Instagram.

CONTACT:
Parexel
Lori Dorer
+1 978 495 4135
lori.dorer@parexel.com

W2O
Lindsay LeCain
+1 508 259 9521
parexelpr@w2ogroup.com

Staff

Recent Posts

Lifeward Announces Postponement of its Extraordinary General Meeting of Shareholders

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq:…

21 hours ago

Psyence Biomed Announces Closing of $2.0 Million Private Placement

NEW YORK, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed”…

21 hours ago

Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.

Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined…

21 hours ago

SAFE GROUP – Half-Year Financial Report as of June 30, 2024

HALF-YEAR FINANCIAL REPORT AS OF JUNE 30, 2024 December 27, 2024, 6.00 p.m. Safe Group announces…

21 hours ago

LYNN STOCKWELL ENTERS INTO A RESTRUCTURING SECURITY AGREEMENT (“RSA”) WITH BRIGHT GREEN CORPORATION AND ASSUMES THE ROLE OF EXECUTIVE CHAIR AND CEO.

GRANTS, NEW MEXICO, Dec. 27, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC: BGXX) (“Bright…

21 hours ago

Judge Baker Children’s Center d/b/a The Baker Center for Children and Families Provides Notice of Data Security Incident

BOSTON, Dec. 27, 2024 /PRNewswire/ -- Judge Baker Children's Center d/b/a The Baker Center for…

1 day ago